|
|
【NOVAMSC 0026 交流专区】荣腾科技
[复制链接]
|
|
|
楼主 |
发表于 12-1-2021 07:31 AM
|
显示全部楼层
| 1. Details of Corporate Proposal | Involve issuance of new type/class of securities ? | No | Types of corporate proposal | Conversion of Preference Shares | Details of corporate proposal | Conversion of Irredeemable Convertible Preference Shares | No. of shares issued under this corporate proposal | 15,435,000 | Issue price per share ($$) | Malaysian Ringgit (MYR) 0.0400 | Par Value($$) (if applicable) |
| | Latest issued share capital after the above corporate proposal in the following | Units | 960,143,370 | Issued Share Capital ($$) | Malaysian Ringgit (MYR) 107,849,132.980 | Listing Date | 11 Sep 2020 |
|
|
|
|
|
|
|
|
|
|
|
|
楼主 |
发表于 14-1-2021 08:27 AM
|
显示全部楼层
Type | Reply to Query | Reply to Bursa Malaysia's Query Letter - Reference ID | IQL-10092020-00002 | Subject | Project awarded by Singapores Building and Construction Authority to develop a localized industry foundation class information model (Contract) | Description | Nova MSC Berhad (NOVAMSC or the Company)Clarification on the article in The New Straits Times dated 3 September 2020 : Nova MSC to localise Singapores IFC data model. | Query Letter Contents | We refer to your Company’s announcement dated 8 September 2020, in respect of the aforesaid matter.
In this connection, kindly furnish Bursa Securities with the following additional information for public release:- - The date on which the Contract was awarded.
- The risks in relation to the Contract.
- The commencement and completion dates of the Contract.
| We refer to our announcement dated 8 September 2020 on the clarification on The New Straits Times article published on 3 September 2020 : “Nova MSC to localize Singapore’s IFC data model” (“Announcement”) and the query from Bursa Securities dated 10 September 2020 in relation to the Announcement (“Query Letter”). Unless otherwise stated, the terms used throughout this announcement shall have the same meanings as defined in the Announcement
We wish to announce the following additional information as required by Bursa Securities pursuant to the Query Letter:
Q1 The date on which the Contract was awarded
The Contract was awarded on 25 August 2020.
Q2 The risks in relation to the Contract
No material risk arising from the Contract is expected, other than the normal operational risk associated with the Contract.
Q3. The commencement and completion dates of the Contract
The Contract commenced on 26 August 2020 and will complete on 28 Feb 2022.
This announcement is dated 11 September 2020.
|
|
|
|
|
|
|
|
|
|
|
|
|
楼主 |
发表于 14-1-2021 08:28 AM
|
显示全部楼层
Type | Reply to Query | Reply to Bursa Malaysia's Query Letter - Reference ID | IQL-10092020-00003 | Subject | Contract awarded to EyRIS Pte Ltd from Integrated Health Information Systems (Contract) | Description | Nova MSC Berhad (NOVAMSC or the Company)Clarification on the article in The StarBiz dated 8 September 2020 : Nova MSC unit wins Spore ministry contract. | Query Letter Contents | We refer to your Company’s announcement dated 8 September 2020, in respect of the aforesaid matter.
In this connection, kindly furnish Bursa Securities with the following additional information for public release:- - The date on which the Contract was awarded.
- The risks in relation to the Contract.
- The commencement and completion dates of the Contract.
- The value of the Contract.
- Details/nature of the Contract.
| We refer to our announcement dated 8 September 2020 on the clarification on the The StarBiz article published on 8 September 2020: “Nova MSC unit wins S’pore ministry contract” (“Announcement”) and the query from Bursa Securities dated 10 September 2020 in relation to the Announcement (“Query Letter”). Unless otherwise stated, the terms used throughout this announcement shall have the same meanings as defined in the Announcement.
We wish to announce the following additional information as required by Bursa Securities pursuant to the Query Letter:
Q1 The date on which the Contract was awarded
The contract (“Contract”) between Integrated Health Information Systems Pte. Ltd. (“IHiS”) and EyRIS Pte. Ltd. (“EyRIS”) was dated 7 September 2020.
Q2 The risks in relation to the Contract
No material risk arising from the Contract is expected, other than the normal operational risk associated with the Contract.
Q3. The commencement and completion dates of the Contract
The Contract commenced on 7 September 2020 and shall continue to be valid and in effect for as long as EyRIS is providing services under the Contract unless terminated prematurely in accordance with the Contract. The Contract envisages, inter alia, services to be provided for at least five (5) years.
Q4 The Value of the Contract
The value of the Contract is currently indeterminate. Under the Contract, the contract price may vary depending on, inter alia, the software and services actually supplied by EyRIS, and the number of patients who use the software.
As disclosed in the Company’s announcement dated 8 September 2020, the Contract is not expected to have any material impact on the Group’s upcoming financial performance.
Q5 Details/nature of the Contract
Under the Contract, EyRIS agreed to, inter alia, (i) supply software to IHiS, including the Singapore Eye Lesion Analyser Plus (SELENA+) software powered by artificial intelligence analytics to detect abnormal fundus images, namely Diabetic Retinopathy, Glaucoma, and Age-Related Macular Degeneration; and (ii) perform certain services in connection with the supply of the software, such as implementation and maintenance and support services. The amount to be paid by IHiS to EyRIS for the software and services may vary depending on, inter alia, the software and services actually supplied by EyRIS, and the number of patients who use the software.
This announcement is dated 11 September 2020.
|
|
|
|
|
|
|
|
|
|
|
|
|
楼主 |
发表于 14-1-2021 08:50 AM
|
显示全部楼层
| 1. Details of Corporate Proposal | Involve issuance of new type/class of securities ? | No | Types of corporate proposal | Conversion of Preference Shares | Details of corporate proposal | Conversion of Irredeemable Convertible Preference Shares | No. of shares issued under this corporate proposal | 23,839,700 | Issue price per share ($$) | Malaysian Ringgit (MYR) 0.0400 | Par Value($$) (if applicable) |
| | Latest issued share capital after the above corporate proposal in the following | Units | 983,983,070 | Issued Share Capital ($$) | Malaysian Ringgit (MYR) 108,564,323.980 | Listing Date | 15 Sep 2020 |
|
|
|
|
|
|
|
|
|
|
|
|
楼主 |
发表于 19-1-2021 04:32 AM
|
显示全部楼层
| 1. Details of Corporate Proposal | Involve issuance of new type/class of securities ? | No | Types of corporate proposal | Conversion of Preference Shares | Details of corporate proposal | Conversion of Irredeemable Convertible Preference Shares | No. of shares issued under this corporate proposal | 13,070,033 | Issue price per share ($$) | Malaysian Ringgit (MYR) 0.0400 | Par Value($$) (if applicable) |
| | Latest issued share capital after the above corporate proposal in the following | Units | 1,003,489,103 | Issued Share Capital ($$) | Malaysian Ringgit (MYR) 109,149,504.970 | Listing Date | 22 Sep 2020 |
|
|
|
|
|
|
|
|
|
|
|
|
楼主 |
发表于 18-3-2021 09:04 AM
|
显示全部楼层
| 1. Details of Corporate Proposal | Involve issuance of new type/class of securities ? | No | Types of corporate proposal | Conversion of Preference Shares | Details of corporate proposal | Conversion of Irredeemable Convertible Preference Shares | No. of shares issued under this corporate proposal | 12,500,000 | Issue price per share ($$) | Malaysian Ringgit (MYR) 0.0400 | Par Value($$) (if applicable) |
| | Latest issued share capital after the above corporate proposal in the following | Units | 1,026,984,103 | Issued Share Capital ($$) | Malaysian Ringgit (MYR) 109,854,354.970 | Listing Date | 28 Oct 2020 |
|
|
|
|
|
|
|
|
|
|
|
|
楼主 |
发表于 18-5-2021 08:10 AM
|
显示全部楼层
本帖最后由 icy97 于 18-7-2021 09:53 AM 编辑
Type | Announcement | Subject | OTHERS | Description | Reseller Agreement between EYRIS Pte Ltd, a subsidiary of Nova MSC Berhad, and Topcon Healthcare Solutions Asia Pte Ltd | INTRODUCTION
The Board of Directors of Nova MSC Berhad (“NOVAMSC”) is pleased to announce that the Company’s subsidiary, EYRIS Pte Ltd (“EYRIS”) has signed a Reseller Agreement (“RA”) with Topcon Healthcare Solutions Asia Pte Ltd (“Topcon”) today.
The press release in respect of the above is also attached herewith for information.
INFORMATION ON TOPCON
Topcon, a company incorporated in Singapore, is a subsidiary of TOPCON Corporation, a company incorporated in Japan, who is the world leading Optomechatronics - Optics, Mechatronics, Electronics - manufacturer since its establishment in 1932. The Topcon name carries a reputation of integrity and products of the highest quality, receiving ISO 9001 certification for both its positioning and medical divisions. Topcon Group has revenues of over $600 million annually and employs over 3,000 people worldwide with 14 domestic subsidiaries, and 26 overseas sales and manufacturing subsidiaries.
SALIENT TERMS OF RA
EYRIS appoints Topcon and Topcon accepts the appointment, as EYRIS’s reseller to market and distribute EYRIS’s products and services (“Products”) directly or through its distribution network in 18 countries in the South and Southeast Asia (including Thailand, India and Hong Kong).
The initial term of this RA begin on 1 November 2020 for a period of seventeen months, ending on 31 March 2022 (“Initial Term”). The RA shall automatically renew for additional one (1) year periods (each, the “Renewal Term”) unless, by giving a written notice at least sixty (60) days prior to the end of the Initial Term or any Renewal Term, either party notifies the other of its decision not to renew.
RATIONALE
The partnership will bring EyRIS SELENA+ to Harmony’s users in 18 countries in South and South East Asia. SELENA+ is a deep learning system (DLS) that can detect 3 types of eye diseases – diabetic retinopathy, glaucoma suspect and age-related macular degeneration. Harmony is an Eye Health Screening solution developed by Topcon that enables screening sites to be linked with eye professionals in a seamless and efficient manner.
RISK FACTORS
NOVAMSC does not expect any material risk arising from the execution of the RA other than the normal credit and operational risk associated with the RA.
FINANCIAL EFFECT OF THE RA
The execution of the RA will not have any effect on the share capital and shareholding structure of NOVAMSC and is not expected to have material effect on the earnings, net assets and gearing of NOVAMSC Group for the financial year ending 31 March 2021. Nonetheless, NOVAMSC expects the RA to contribute positively to the overall earnings in the future.
DIRECTORS AND MAJOR SHAREHOLDERS’ INTERESTS
None of the directors, major shareholders and persons connected with a director or a major shareholder of NOVAMSC has any interest, direct or indirect in the RA.
STATEMENT BY DIRECTORS
The Board, having taken into consideration of all aspects of the RA, is of the opinion that the RA is in the best interest of NOVAMSC.
This announcement is dated 12 November 2020. |
https://www.bursamalaysia.com/market_information/announcements/company_announcement/announcement_details?ann_id=3104665
| 1. Details of Corporate Proposal | Involve issuance of new type/class of securities ? | No | Types of corporate proposal | Conversion of Preference Shares | Details of corporate proposal | Conversion of Irredeemable Convertible Preference Shares | No. of shares issued under this corporate proposal | 11,500,000 | Issue price per share ($$) | Malaysian Ringgit (MYR) 0.0400 | Par Value($$) (if applicable) |
| | Latest issued share capital after the above corporate proposal in the following | Units | 1,040,424,103 | Issued Share Capital ($$) | Malaysian Ringgit (MYR) 110,257,554.970 | Listing Date | 18 Nov 2020 |
| 1. Details of Corporate Proposal | Involve issuance of new type/class of securities ? | No | Types of corporate proposal | Conversion of Preference Shares | Details of corporate proposal | Conversion of Irredeemable Convertible Preference Shares | No. of shares issued under this corporate proposal | 15,985,000 | Issue price per share ($$) | Malaysian Ringgit (MYR) 0.0400 | Par Value($$) (if applicable) |
| | Latest issued share capital after the above corporate proposal in the following | Units | 1,056,409,103 | Issued Share Capital ($$) | Malaysian Ringgit (MYR) 110,737,104.970 | Listing Date | 20 Nov 2020 |
SUMMARY OF KEY FINANCIAL INFORMATION
30 Sep 2020 |
| | INDIVIDUAL PERIOD | CUMULATIVE PERIOD | CURRENT YEAR QUARTER | PRECEDING YEAR
CORRESPONDING
QUARTER | CURRENT YEAR TO DATE | PRECEDING YEAR
CORRESPONDING
PERIOD | 30 Sep 2020 | 30 Sep 2019 | 30 Sep 2020 | 30 Sep 2019 | $$'000 | $$'000 | $$'000 | $$'000 |
| 1 | Revenue | 9,025 | 9,819 | 18,250 | 22,806 | | 2 | Profit/(loss) before tax | 71 | 1,045 | 607 | 1,876 | | 3 | Profit/(loss) for the period | 71 | 1,045 | 607 | 1,876 | | 4 | Profit/(loss) attributable to ordinary equity holders of the parent | 130 | 1,223 | 780 | 2,060 | | 5 | Basic earnings/(loss) per share (Subunit) | 0.01 | 0.16 | 0.09 | 0.27 | | 6 | Proposed/Declared dividend per share (Subunit) | 0.00 | 0.00 | 0.00 | 0.00 |
|
| AS AT END OF CURRENT QUARTER | AS AT PRECEDING FINANCIAL YEAR END | 7
| Net assets per share attributable to ordinary equity holders of the parent ($$) | 0.0733 | 0.0872
|
| 1. Details of Corporate Proposal | Involve issuance of new type/class of securities ? | No | Types of corporate proposal | Conversion of Preference Shares | Details of corporate proposal | Conversion of Irredeemable Convertible Preference Shares | No. of shares issued under this corporate proposal | 14,837,000 | Issue price per share ($$) | Malaysian Ringgit (MYR) 0.0400 | Par Value($$) (if applicable) |
| | Latest issued share capital after the above corporate proposal in the following | Units | 1,079,089,003 | Issued Share Capital ($$) | Malaysian Ringgit (MYR) 111,417,501.970 | Listing Date | 07 Dec 2020 |
Type | Announcement | Subject | OTHERS | Description | Novacitynets Pte Ltd, a wholly owned subsidiary of Nova MSC Berhad, awarded contract from Singapore's Building and Construction Authority | The Board of Directors of Nova MSC Berhad ("Company") is pleased to announce that the Company’s wholly-owned subsidiary novaCITYNETS Pte Ltd (“NCN”) has been notified by Building and Construction Authority in Singapore (“BCA”) on 7th December 2020 that NCN has been awarded a pilot trial contract amounting to approximately RM5.0 million (approximately S$1.64 million) from 1 Jan 2021 to 31 December 2021 (“Pilot Trial Contract”) for an outcome-based procurement for the supply, delivery, installation, testing and commissioning of fully operational model checker of Corenet X with an option for maintenance (“Model Checker Project”).
After the expiry of the Pilot Trial Contract, BCA will decide whether to issue any final award (“Final Phase”) for the Model Checker Project. NCN had submitted a tender sum of approximately RM119.93 million (approximately S$39.32 million) for the Final Phase of the Model Checker Project to be implemented and maintained over the next 81 months. NCN would like to highlight that the award of the Pilot Trial Contract does not constitute a final award to NCN to supply the Model Checker Project and BCA is also not obliged to issue any final award to NCN for the Model Checker Project after the expiry of the Pilot Trial Contract.
NCN does not expect any material risk arising from the Pilot Trial Contract other than the normal operational and execution risk associated with the contract.
The Pilot Trial Contract will not have any effect on the share capital and shareholding structure of Nova MSC Bhd. The Pilot Trial Contract is not expected to contribute materially to the result of the Group for the financial year ending 31 March 2021.
None of the directors and/or substantial shareholders of Nova MSC Berhad or persons connected to the said directors and/or substantial shareholders have any interest, direct or indirect in the new contract awarded.
This announcement is dated 8th December 2020. |
|
|
|
|
|
|
|
|
|
|
|
|
楼主 |
发表于 21-10-2021 07:43 AM
|
显示全部楼层
Date of change | 20 Oct 2021 | Name | MR TAN YEW SOON | Age | 59 | Gender | Male | Nationality | Singapore | Type of change | Cessation Of Office | Designation | Chief Operating Officer | Reason | To pursue other personal interest | Details of any disagreement that he/she has with the Board of Directors | No | Whether there are any matters that need to be brought to the attention of shareholders | No |
Qualifications| No | Qualifications | Major/Field of Study | Institute/University | Additional Information |
| | | Details of any interest in the securities of the listed issuer or its subsidiaries | 70 Ordinary Shares |
| Remarks : | | Mr Tan Yew Soon will step down as the Group Chief Operating Officer (GCOO) with immediate effect.He has also resigned as the Chief Executive Officer (CEO) of novaCITYNETS Pte Ltd (NCN). He will serve the contractual 3 months notice and will be working closely with the Board to ensure an orderly and smooth transitionThe job and responsibilities of Mr Tan will be assigned to other management staff in the Group subsequent to his cessation as the GCOO and CEO of NCN. |
|
|
|
|
|
|
|
|
|
|
|
|
楼主 |
发表于 11-1-2022 09:16 AM
|
显示全部楼层
SUMMARY OF KEY FINANCIAL INFORMATION
30 Sep 2021 |
| | INDIVIDUAL PERIOD | CUMULATIVE PERIOD | CURRENT YEAR QUARTER | PRECEDING YEAR
CORRESPONDING
QUARTER | CURRENT YEAR TO DATE | PRECEDING YEAR
CORRESPONDING
PERIOD | 30 Sep 2021 | 30 Sep 2020 | 30 Sep 2021 | 30 Sep 2020 | $$'000 | $$'000 | $$'000 | $$'000 |
| 1 | Revenue | 9,242 | 9,025 | 16,560 | 18,250 | | 2 | Profit/(loss) before tax | -1,736 | 71 | -4,763 | 607 | | 3 | Profit/(loss) for the period | -1,736 | 71 | -4,763 | 607 | | 4 | Profit/(loss) attributable to ordinary equity holders of the parent | -1,374 | 130 | -4,327 | 780 | | 5 | Basic earnings/(loss) per share (Subunit) | -0.12 | 0.01 | -0.38 | 0.09 | | 6 | Proposed/Declared dividend per share (Subunit) | 0.00 | 0.00 | 0.00 | 0.00 |
|
| AS AT END OF CURRENT QUARTER | AS AT PRECEDING FINANCIAL YEAR END | 7
| Net assets per share attributable to ordinary equity holders of the parent ($$) | 0.0555 | 0.0597
|
|
|
|
|
|
|
|
|
|
|
|
|
楼主 |
发表于 8-9-2023 11:33 AM
|
显示全部楼层
Type | Announcement | Subject | OTHERS | Description | NOVA MSC BERHAD ("NOVA" OR "THE COMPANY")- JOINT VENTURE AND SHAREHOLDERS' AGREEMENT BETWEEN THETA EDGE BERHAD AND NOVA MSC BERHAD | 1. INTRODUCTION The Board of Directors of NOVA is pleased to announce that NOVA had on 5 September 2023 entered into a Joint Venture & Shareholders’ Agreement (“JVSA”) with Theta Edge Berhad (“TEB”) (collectively referred to as the “Parties”) to regulate the rights and relationship of TEB and NOVA inter se as shareholders of the joint venture company (“JVCo”) upon its incorporation, to regulate the rights and obligations of TEB and NOVA in respect of the JVCo, upon its incorporation and to bind each other to their obligations upon the terms and conditions stipulated in the JVSA (“Joint Venture”).
2 RATIONALE FOR THE JOINT VENTURE The Joint Venture is expected to pave the way for future collaboration between the Parties to identify and procure future project(s) for the JVCo, which is consistent with the objectives of NOVA in seeking strategic alliances from time to time for mutual benefits.
It is the intention of TEB and NOVA to cooperate for the purpose of providing e-government solutions and/or other IT solutions, including system integration, outsourcing, consultancy and infrastructure system services, on a commercially viable basis in Malaysia and/or other countries as determined by the JVCo.
3. INFORMATION ON TEB THETA is one of Malaysia’s pioneer Information Communication and Technology (ICT) Service Provider. The company made its debut on the Second Board of the Kuala Lumpur Stock Exchange in 1994 and moved to the Main Board in 1999 and currently is categorized under the Technology sector of the main market of Bursa Malaysia Securities Berhad. The Group has been in business for more than 30 years focusing on the following: - - Information Technology Solutions
- Telecommunication Engineering Services & Civil Works
- Green Energy Consultant and System Integrator
4. SALIENT TERMS OF THE JVSA The salient terms as extracted from the JVSA include, inter-alia, the following:
4.1 The leading partner for the joint venture shall be NOVA. The Parties agree to collaborate in forming the joint venture to procure project(s) for the JVCo and to undertake and perform the project(s) and the services thereunder using the JVCo. TEB and NOVA shall be jointly and severally liable to the JVCo for all obligations of the JVCo.
4.2 The joint venture shall commence from the date of the JVSA and shall continue to be effective unless terminated in accordance with the provisions in the JVSA.
4.3 The JVCo shall have an equity shareholding structure of TEB: 60% and NOVA: 40% (“Respective Proportions”) during the entire duration of the JVSA. The shares to be held by the Parties in the JVCO will be as follows:
Shareholder | No. of shares | Amount (RM) | Shareholding Percentage (%) | TEB | 60,000,000 | 9,000,000 | 60 | NOVA | 40,000,000 | 6,000,000 | 40 | Total | 100,000,000 | 15,000,000 | 100 |
Any new shares shall be first offered to each of the shareholders in their Respective Proportions and if any shareholder fails to subscribe, its shareholding in the JVCo will be diluted and the other shareholder may subscribe for such new shares.
The cash contribution by TEB would be made in stages upon the requirement by the Board of Directors of the JVCo based on the JVCo’s business plan. NOVA’s capital contribution shall be made through the transfer of NOVA’s IP for the Malaysian region and shall be made upon requirement of equity capitalization for the purpose of execution of the Project and formalization of transfers to the JVCo. 4.4 The board of the JVCo shall comprise a maximum of 5 directors, TEB shall be entitled to appoint up to 3 directors and NOVA up to 2 directors. The chairman of the board of the JVCo shall be from TEB directors. Except for directors reserved matters, the decisions of the board shall be based on simple majority of votes of the directors present. 4.5 The directors reserved matters can only be passed with the unanimous decision of the directors. 4.6 The quorum at any general meeting is at least 2 shareholders, i.e. both TEB and NOVA. Members’ resolution shall be passed by simple majority except for where a majority of not less than 75% is prescribed by the Companies Act 2016.
5. RISK FACTORS NOVA does not foresee any exceptional risk other than operational risk associated with the proposed JV Co which are similar to the operational risks that NOVA is already accustomed to. Hence the Board believes that the experience and expertise of its management team will enable the Group to mitigate these risks effectively.
6. EFFECTS OF THE JOINT VENTURE The Joint Venture has no effect on the issued and paid-up share capital and the substantial shareholders’ shareholding of NOVA.
The JV Co will become a 40% owned company of NOVA. In the event the JVCo is awarded any project(s), then barring any unforeseen circumstances, the JVCo is expected to contribute positively to NOVA Group consolidated earnings and earnings per share in the future arising from any profits derived from the project(s).
7. DIRECTORS' AND SUBSTANTIAL SHAREHOLDERS' INTERESTS None of the Directors and/or substantial shareholders of NOVA and/or persons connected with such Directors or substantial shareholders have any interest, either directly or indirectly, in the Joint Venture.
8. APPROVALS REQUIRED The Joint Venture does not require the approval of the shareholders of NOVA or any authority.
9. STATEMENT BY DIRECTORS The Board of Directors of NOVA is of the opinion that the Joint Venture is in the best interest of NOVA.
This announcement is dated 5 September 2023 |
Type | Announcement | Subject | OTHERS | Description | NOVA MSC BERHAD ("NOVA" or "The Company) - PRESS RELEASE | Nova MSC and Theta Edge Form Strategic Joint Venture to Revolutionise e-Government and Advanced IT Solutions in Malaysia
Please refer to the attachment for the details of the press release.
This announcement is dated 5 September 2023 |
https://www.bursamalaysia.com/market_information/announcements/company_announcement/announcement_details?ann_id=3383508
|
|
|
|
|
|
|
|
|
|
|
|
楼主 |
发表于 7-10-2023 06:40 AM
|
显示全部楼层
Type | Announcement | Subject | NEW ISSUE OF SECURITIES (CHAPTER 6 OF LISTING REQUIREMENTS)
FUND RAISING | Description | NOVA MSC BERHAD ("NOVAMSC" OR THE "COMPANY")PROPOSED PLACEMENT OF NEW ORDINARY SHARES IN NOVAMSC ("SHARES" OR "NOVAMSC SHARES") ("PLACEMENT SHARES") OF UP TO 10% OF NOVAMSC'S ISSUED SHARES ("PROPOSED PLACEMENT") | On behalf of the Board of Directors of NovaMSC (“Board”), Mercury Securities Sdn Bhd (“Mercury Securities”) wishes to announce that the Company proposes to undertake the Proposed Placement.
Please refer to the attachment for further details on the Proposed Placement.
This announcement is dated 6 October 2023. |
https://www.bursamalaysia.com/market_information/announcements/company_announcement/announcement_details?ann_id=3390782
|
|
|
|
|
|
|
|
|
|
|
|
楼主 |
发表于 21-4-2024 10:06 AM
|
显示全部楼层
Type | Announcement | Subject | OTHERS | Description | Nova MSC Berhad (NOVAMSC or Company)Term Sheets With Jostar Investment VCC | 1. Introduction
The Board of Directors of NOVAMSC wishes to announce the execution of the following Term Sheets by its subsidiary companies on 19 April 2024:
(i) Term Sheet between Dex-Lab Pte. Ltd. (“Dex-Lab”), a 60% owned subsidiary of the Company and Jostar Investment VCC (Registration No. T24VC0046J) (“Jostar”) (collectively, “TS1”).
TS1 records Jostar’s desire to invest into Dex-Lab with an investment amount of SGD5.0 million (approximately RM17.5 million) in a single or multiple tranches subject to the finalised valuation of Dex-Lab as of the closure date of the accounting due diligence, and negotiation between the parties.
(ii) Term Sheet between EyRIS Pte. Ltd., a 42% owned subsidiary of the Company (“EyRIS”) and Jostar (collectively, “TS2”).
TS2 records Jostar’s desire to invest into EyRIS with an investment amount of USD5.0 million (approximately RM23.9 million) in a single or multiple tranches subject to the finalised valuation of EyRIS as of the closure date of the accounting due diligence, and negotiation between the parties.
TS1 and TS2 are both independent and are not inter-related to each other. They only served as the basis for further discussions, negotiation and execution of definitive agreements, completion of due diligence, and fulfilment of any regulatory requirements, and shall not be construed as an intention to create any legally binding obligation on or agreement between the parties to proceed therewith unless and until such time as definitive agreements are executed. The investment process is estimated to be completed before 31 July 2024.
2. Information on Jostar
Jostar is a single-family office formed under the framework of a Variable Capital Company. It is domiciled in the Republic of Singapore. Its core activities are to seek out high growth private companies and to partake in their growth through equity investment into the company.
3. Further Announcement
The Company will make further announcements upon the execution of the definitive agreements and/or when there is any material development in connection with the TS1 and/or TS2, as and when appropriate.
4. Interests of Directors and major shareholders
None of the Directors and/or major shareholders of NOVAMSC and/or persons connected with the Directors and/or major shareholders of NOVAMSC, has any interest, direct or indirect in the entry of the TS1 and/or TS2.
This announcement is dated 19 April 2024.
|
|
|
|
|
|
|
|
|
|
|
|
|
楼主 |
发表于 12-9-2024 06:31 AM
|
显示全部楼层
SUMMARY OF KEY FINANCIAL INFORMATION
30 Jun 2024 |
| | INDIVIDUAL PERIOD | CUMULATIVE PERIOD | CURRENT YEAR QUARTER | PRECEDING YEAR
CORRESPONDING
QUARTER | CURRENT YEAR TO DATE | PRECEDING YEAR
CORRESPONDING
PERIOD | 30 Jun 2024 | 30 Jun 2023 | 30 Jun 2024 | 30 Jun 2023 | $$'000 | $$'000 | $$'000 | $$'000 |
| 1 | Revenue | 7,702 | 7,437 | 7,702 | 7,437 | | 2 | Profit/(loss) before tax | -3,195 | -1,983 | -3,195 | -1,983 | | 3 | Profit/(loss) for the period | -3,195 | -1,983 | -3,195 | -1,983 | | 4 | Profit/(loss) attributable to ordinary equity holders of the parent | -2,807 | -1,954 | -2,807 | -1,954 | | 5 | Basic earnings/(loss) per share (Subunit) | -0.23 | -0.16 | -0.23 | -0.16 | | 6 | Proposed/Declared dividend per share (Subunit) | 0.00 | 0.00 | 0.00 | 0.00 |
|
| AS AT END OF CURRENT QUARTER | AS AT PRECEDING FINANCIAL YEAR END | 7
| Net assets per share attributable to ordinary equity holders of the parent ($$) | 0.0245 | 0.0261
|
|
|
|
|
|
|
|
|
|
|
|
|
楼主 |
发表于 17-9-2024 04:44 PM
|
显示全部楼层
| 1. Details of Corporate Proposal | Involve issuance of new type/class of securities ? | No | Types of corporate proposal | Conversion of Preference Shares | Details of corporate proposal | Conversion of Irredeemable Convertible Preference Shares | No. of shares issued under this corporate proposal | 13,760,000 | Issue price per share ($$) | Malaysian Ringgit (MYR) 0.0400 | Par Value($$) (if applicable) |
| | Latest issued share capital after the above corporate proposal in the following | Units | 1,341,592,682 | Issued Share Capital ($$) | Malaysian Ringgit (MYR) 121,524,669.290 | Listing Date | 09 Sep 2024 |
|
|
|
|
|
|
|
|
|
|
|
|
楼主 |
发表于 19-9-2024 07:54 PM
|
显示全部楼层
Type | Announcement | Subject | OTHERS | Description | NOVA MSC BERHAD (NOVAMSC OR THE COMPANY)EYRIS Pte Ltd, a subsidiary of NOVAMSC, secures RM7.13 million project order in Brunei Darussalam | The Board of Directors of the Company is pleased to announce that its subsidiary, EYRIS Pte Ltd (“EYRIS”), has received an order from JPMCnova Sdn Bhd (“JPMCnova”), valued at RM7.13 million as of today. This award is for the rollout of the National Diabetic Retinopathy (“NDR”) Screening Program in Brunei Darussalam (“the Project”). Please refer to the attached press release for further details.
The Project involves EYRIS collaborating with JPMCnova to implement a comprehensive NDR screening program for Ministry of Health, Brunei Darussalam. This program will cover all hospitals and healthcare centres, utilizing our cloud-based SELENA+ and EySCAN tele-ophthalmology platform for efficient screening and monitoring. The Project will commence from 1 October 2024 and will run for 5 years.
EYRIS does not expect any material risk arising from the Project other than the normal operational and execution risk associated with the Project.
The Project will not have any effect on the share capital and shareholding structure of the Company. The Project is expected to contribute positively to the result of the Group over the period.
None of the directors and/or substantial shareholders of NMSC or persons connected to the said directors and/or substantial shareholders have any interest, direct or indirect, in the new order awarded.
This announcement is dated 9 September 2024.
About JPMCnova
JPMCnova Sdn Bhd is a 49% associate company of Novahealth Pte Ltd, which is a wholly-owned subsidiary of Nova MSC Berhad. The other major shareholder, holding 51%, is Jerudong Park Medical Centre. Established in Brunei Darussalam in 2010, JPMCnova Sdn Bhd primarily operates as a solutions provider for medical and healthcare institutions, with a focus on industry-related services and innovations. |
https://www.bursamalaysia.com/market_information/announcements/company_announcement/announcement_details?ann_id=3482173
|
|
|
|
|
|
|
|
|
|
| |
 本周最热论坛帖子
|
2335 
43
